论文部分内容阅读
1971年国产聚肌胞(Poly l:C)试制成功,并投入临床应用,对乙型肝炎的临床疗效已有报道。我们自1982年初至1983年7月应用天津生化制药厂生产的聚肌胞注射液治疗40例HBsAg 阳性慢性肝炎,重点观察HBsAg 和抗-HBc 的滴度变化以及HBeAg 的变化,并与25例同类患者进行比较,观察抗病毒效果。研究对象治疗组:40例均为我院肝炎随访门诊患者,按1978年全国肝炎会议制订的诊断标准,选择肝功能异常病程超过1年以上的HBsAg
In 1971 Poly polyculture (Poly l: C) trial success, and put into clinical application, the clinical efficacy of hepatitis B has been reported. From early 1982 to July 1983, poly-myosin injection from Tianjin Biochemical Pharmaceutical Factory was used to treat 40 cases of HBsAg-positive chronic hepatitis. The titer of HBsAg and anti-HBc as well as the change of HBeAg were observed. Patients were compared to observe the anti-virus effect. Study group: 40 cases were followed-up inpatients with hepatitis in our hospital. According to the diagnostic criteria formulated by the National Hepatitis Congress in 1978, HBsAg with abnormal liver function over one year